A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset
name of Cycloset
tablet, from S2 Therapeutics and VeroScience, at five
Now, the company's product portfolio offers 22 marketed products, including XIFAXAN, UCERIS, GLUMETZA, APRISO, ZEGERID, MOVIPREP, RELISTOR, SOLESTA, FULYZAQ, CYCLOSET
License fees and royalties include royalties on GLUMETZA net sales, the gross margin split on CYCLOSET
net sales, royalties on ZEGERID net sales and amortization of upfront payments.
rights to Cycloset
and plans to start selling the drug in November.
is the first approved treatment for type 2 diabetes that seeks to improve dopamine activity in the brain--which studies have linked to better insulin control.
But unlike its older parent, Cycloset
is formulated to require a low, quick-acting dose taken just in the morning -- no other time of day.
7) In the Cycloset
Safety Study, for instance, bromocriptine QR combined with standard diabetes therapy (diet plus oral hypoglycemic agents as needed) was compared with standard diabetes therapy plus placebo in more than 3,000 patients.
M2 PHARMA-November 15, 2010-Santarus launches Type 2 diabetes drug CYCLOSET
in USA(C)2010 M2 COMMUNICATIONS
M2 EQUITYBITES-September 9, 2010-Santarus Inc licenses CYCLOSET
for type 2 diabetes(C)2010 M2 COMMUNICATIONS http://www.
9 September 2010 - US-based biopharmaceutical company Santarus Inc (NASDAQ: SNTS), S2 Therapeutics Inc and VeroScience LLC today announced they have entered into a distribution and licence agreement granting Santarus exclusive rights to manufacture and commercialise CYCLOSET
tablets in USA.
, a quick-release oral formulation of bromocriptine mesylate, was recently approved by the Food and Drug Administration as a treatment for type 2 diabetes, according to the manufacturers, VeroScience and S2 Therapeutics Inc.